Expert Interview
Discussing the potential of Lilly's Donanemab based on the Phase 3 TRAILBLAZER-ALZ 2 study after FDA adcomm backs drug
Ticker(s): LLYInstitution: UC Health
- Professor and Endowed Chair of the James J. and Joan A. Gardner Center for Parkinson's Disease at the University of Cincinnati.
- Treats 150 - 200 patients with Alzheimer’s Disease
- Research interest includes movement disorders, biomarkers, Parkinson’s disease, and Alzheimer’s disease.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
